Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ketamine | 27 | 2023 | 208 | 10.690 |
Why?
|
| Depressive Disorder, Major | 25 | 2024 | 383 | 7.620 |
Why?
|
| Stress Disorders, Post-Traumatic | 32 | 2024 | 616 | 7.040 |
Why?
|
| Antidepressive Agents | 24 | 2022 | 283 | 5.720 |
Why?
|
| Glutamic Acid | 13 | 2024 | 200 | 3.490 |
Why?
|
| Connectome | 6 | 2023 | 78 | 3.290 |
Why?
|
| Excitatory Amino Acid Antagonists | 11 | 2019 | 95 | 3.120 |
Why?
|
| Brain | 24 | 2024 | 2944 | 2.950 |
Why?
|
| Prefrontal Cortex | 15 | 2024 | 170 | 2.930 |
Why?
|
| Hippocampus | 14 | 2024 | 805 | 2.060 |
Why?
|
| Stress, Psychological | 12 | 2024 | 556 | 1.790 |
Why?
|
| Military Personnel | 5 | 2023 | 205 | 1.730 |
Why?
|
| Nerve Net | 4 | 2020 | 233 | 1.700 |
Why?
|
| Magnetic Resonance Imaging | 31 | 2024 | 3433 | 1.700 |
Why?
|
| Veterans | 10 | 2023 | 1707 | 1.590 |
Why?
|
| Depression | 11 | 2024 | 1205 | 1.580 |
Why?
|
| Cerebral Cortex | 5 | 2020 | 444 | 1.500 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2020 | 105 | 1.440 |
Why?
|
| Occipital Lobe | 4 | 2014 | 32 | 1.380 |
Why?
|
| Magnetic Resonance Spectroscopy | 9 | 2024 | 286 | 1.110 |
Why?
|
| Neuroimaging | 10 | 2024 | 325 | 1.090 |
Why?
|
| Receptors, Glutamate | 2 | 2024 | 16 | 1.090 |
Why?
|
| Synaptic Transmission | 6 | 2020 | 348 | 1.080 |
Why?
|
| Schizophrenia | 4 | 2022 | 296 | 1.070 |
Why?
|
| Depressive Disorder | 3 | 2020 | 450 | 1.050 |
Why?
|
| Neuronal Plasticity | 3 | 2020 | 272 | 1.020 |
Why?
|
| White Matter | 5 | 2024 | 181 | 0.980 |
Why?
|
| Humans | 86 | 2024 | 121743 | 0.980 |
Why?
|
| Neural Pathways | 4 | 2019 | 262 | 0.970 |
Why?
|
| Hallucinogens | 2 | 2022 | 40 | 0.900 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 115 | 0.870 |
Why?
|
| Aspartic Acid | 6 | 2015 | 75 | 0.860 |
Why?
|
| Glutamates | 2 | 2023 | 69 | 0.820 |
Why?
|
| Riluzole | 2 | 2012 | 21 | 0.820 |
Why?
|
| Anxiety Disorders | 6 | 2017 | 675 | 0.810 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2022 | 145 | 0.800 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2024 | 165 | 0.770 |
Why?
|
| Adult | 37 | 2024 | 28623 | 0.710 |
Why?
|
| Tobacco Use Disorder | 1 | 2021 | 86 | 0.710 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 139 | 0.690 |
Why?
|
| Neurobiology | 5 | 2020 | 25 | 0.690 |
Why?
|
| Neurotransmitter Agents | 2 | 2024 | 144 | 0.670 |
Why?
|
| Psychiatry | 1 | 2023 | 263 | 0.660 |
Why?
|
| Smoking Cessation | 1 | 2021 | 194 | 0.650 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2018 | 36 | 0.650 |
Why?
|
| Secondary Prevention | 1 | 2020 | 209 | 0.630 |
Why?
|
| Cerebellum | 3 | 2024 | 410 | 0.620 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 6 | 2024 | 28 | 0.620 |
Why?
|
| Brain Mapping | 7 | 2024 | 393 | 0.590 |
Why?
|
| War Exposure | 1 | 2017 | 8 | 0.570 |
Why?
|
| Nucleus Accumbens | 1 | 2017 | 54 | 0.560 |
Why?
|
| Psychological Trauma | 1 | 2017 | 18 | 0.560 |
Why?
|
| Male | 45 | 2024 | 59138 | 0.560 |
Why?
|
| Young Adult | 17 | 2022 | 8712 | 0.550 |
Why?
|
| Organ Size | 6 | 2024 | 411 | 0.550 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 35 | 0.550 |
Why?
|
| Norepinephrine | 2 | 2018 | 175 | 0.540 |
Why?
|
| Pulmonary Surfactants | 1 | 2016 | 43 | 0.540 |
Why?
|
| Pneumothorax | 1 | 2016 | 80 | 0.510 |
Why?
|
| Emotions | 4 | 2024 | 362 | 0.510 |
Why?
|
| Pilot Projects | 7 | 2023 | 1357 | 0.510 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 804 | 0.500 |
Why?
|
| Foreign Bodies | 1 | 2016 | 102 | 0.500 |
Why?
|
| Middle Aged | 25 | 2024 | 25388 | 0.490 |
Why?
|
| Female | 40 | 2024 | 64492 | 0.490 |
Why?
|
| Cognition | 2 | 2019 | 732 | 0.480 |
Why?
|
| Airway Obstruction | 1 | 2016 | 165 | 0.470 |
Why?
|
| Diffusion Tensor Imaging | 6 | 2020 | 237 | 0.440 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 285 | 0.430 |
Why?
|
| Anesthetics, Dissociative | 1 | 2012 | 20 | 0.410 |
Why?
|
| Schizophrenic Psychology | 2 | 2010 | 80 | 0.410 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 569 | 0.400 |
Why?
|
| Anti-Anxiety Agents | 1 | 2012 | 72 | 0.400 |
Why?
|
| Treatment Outcome | 9 | 2022 | 11685 | 0.390 |
Why?
|
| Electroconvulsive Therapy | 1 | 2012 | 65 | 0.390 |
Why?
|
| Borderline Personality Disorder | 1 | 2014 | 146 | 0.370 |
Why?
|
| Mental Disorders | 2 | 2016 | 822 | 0.370 |
Why?
|
| Biomarkers | 7 | 2023 | 2922 | 0.370 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1564 | 0.360 |
Why?
|
| Synapses | 2 | 2024 | 440 | 0.360 |
Why?
|
| Animals | 19 | 2024 | 33670 | 0.360 |
Why?
|
| Gap Junctions | 1 | 2010 | 35 | 0.350 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 162 | 0.350 |
Why?
|
| Mitochondria | 1 | 2014 | 666 | 0.340 |
Why?
|
| Neurons | 1 | 2019 | 1916 | 0.340 |
Why?
|
| Anesthesia | 1 | 2012 | 209 | 0.340 |
Why?
|
| Social Adjustment | 1 | 2009 | 84 | 0.330 |
Why?
|
| Anisotropy | 4 | 2020 | 120 | 0.330 |
Why?
|
| Sirolimus | 2 | 2022 | 221 | 0.330 |
Why?
|
| Independent Living | 1 | 2009 | 65 | 0.330 |
Why?
|
| Functional Neuroimaging | 3 | 2017 | 30 | 0.320 |
Why?
|
| Positron-Emission Tomography | 4 | 2024 | 285 | 0.310 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 139 | 0.310 |
Why?
|
| Case-Control Studies | 8 | 2022 | 3221 | 0.300 |
Why?
|
| Residence Characteristics | 1 | 2009 | 265 | 0.290 |
Why?
|
| Corpus Callosum | 3 | 2020 | 98 | 0.290 |
Why?
|
| Functional Laterality | 4 | 2017 | 178 | 0.280 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 2 | 2017 | 13 | 0.260 |
Why?
|
| Smoking | 2 | 2021 | 1027 | 0.250 |
Why?
|
| Aged | 10 | 2022 | 18464 | 0.250 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 347 | 0.240 |
Why?
|
| Choline | 3 | 2015 | 55 | 0.240 |
Why?
|
| Aging | 3 | 2023 | 1157 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 2792 | 0.230 |
Why?
|
| Exposure to Violence | 1 | 2024 | 8 | 0.230 |
Why?
|
| Epilepsies, Partial | 1 | 2024 | 91 | 0.220 |
Why?
|
| Macaca radiata | 6 | 2015 | 15 | 0.220 |
Why?
|
| Amygdala | 3 | 2024 | 76 | 0.210 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 208 | 0.210 |
Why?
|
| Self-Injurious Behavior | 1 | 2023 | 62 | 0.200 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 22 | 0.200 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2023 | 202 | 0.200 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2021 | 11 | 0.200 |
Why?
|
| Combat Disorders | 1 | 2021 | 22 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 259 | 0.190 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 200 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 3286 | 0.180 |
Why?
|
| Habenula | 1 | 2021 | 45 | 0.180 |
Why?
|
| Gyrus Cinguli | 3 | 2017 | 114 | 0.180 |
Why?
|
| Benzodiazepines | 2 | 2018 | 98 | 0.180 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2020 | 16 | 0.180 |
Why?
|
| Laburnum | 1 | 2019 | 2 | 0.170 |
Why?
|
| Creatine | 3 | 2015 | 41 | 0.170 |
Why?
|
| Gray Matter | 2 | 2024 | 30 | 0.170 |
Why?
|
| Psychotherapy | 1 | 2022 | 222 | 0.170 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 42 | 0.170 |
Why?
|
| Adolescent | 9 | 2024 | 18879 | 0.160 |
Why?
|
| Mood Disorders | 3 | 2015 | 123 | 0.160 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2018 | 18 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 302 | 0.160 |
Why?
|
| Cluster Analysis | 1 | 2019 | 386 | 0.160 |
Why?
|
| Health Surveys | 1 | 2019 | 235 | 0.150 |
Why?
|
| Anxiety | 2 | 2017 | 947 | 0.150 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 22 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 130 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 539 | 0.150 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 15 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 173 | 0.140 |
Why?
|
| Intelligence | 1 | 2017 | 98 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 71 | 0.140 |
Why?
|
| Hypertrophy | 1 | 2017 | 99 | 0.140 |
Why?
|
| Electroencephalography | 3 | 2024 | 842 | 0.130 |
Why?
|
| Models, Neurological | 1 | 2017 | 202 | 0.130 |
Why?
|
| Epilepsy | 1 | 2024 | 852 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 804 | 0.130 |
Why?
|
| Maternal Deprivation | 2 | 2013 | 13 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 221 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 1144 | 0.130 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2015 | 13 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2017 | 301 | 0.130 |
Why?
|
| Parietal Lobe | 1 | 2015 | 41 | 0.130 |
Why?
|
| Arousal | 1 | 2016 | 80 | 0.130 |
Why?
|
| Research Design | 1 | 2019 | 643 | 0.130 |
Why?
|
| Suicide, Attempted | 2 | 2023 | 125 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1680 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 114 | 0.120 |
Why?
|
| Hydrocortisone | 1 | 2015 | 215 | 0.120 |
Why?
|
| Citric Acid Cycle | 1 | 2014 | 44 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1032 | 0.120 |
Why?
|
| Internal Capsule | 2 | 2015 | 51 | 0.120 |
Why?
|
| Protons | 1 | 2014 | 92 | 0.120 |
Why?
|
| Carbon Isotopes | 1 | 2014 | 272 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2019 | 4635 | 0.110 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2011 | 58 | 0.110 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 42 | 0.110 |
Why?
|
| Seizures | 2 | 2024 | 874 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2018 | 740 | 0.110 |
Why?
|
| Corticosterone | 1 | 2013 | 61 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1275 | 0.110 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2021 | 767 | 0.110 |
Why?
|
| Thiopental | 1 | 2012 | 5 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1241 | 0.100 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2012 | 10 | 0.100 |
Why?
|
| Sensory Gating | 1 | 2012 | 14 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4278 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 349 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 134 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 339 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2016 | 799 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 44 | 0.090 |
Why?
|
| Social Desirability | 1 | 2009 | 18 | 0.090 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2009 | 43 | 0.080 |
Why?
|
| Models, Biological | 1 | 2014 | 1434 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 870 | 0.080 |
Why?
|
| Social Environment | 1 | 2009 | 119 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2059 | 0.080 |
Why?
|
| Urban Population | 1 | 2010 | 216 | 0.080 |
Why?
|
| Peer Group | 1 | 2009 | 118 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 125 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 367 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 322 | 0.070 |
Why?
|
| Fear | 2 | 2024 | 198 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 394 | 0.070 |
Why?
|
| Pediatrics | 1 | 2016 | 1137 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2010 | 1004 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 6098 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 857 | 0.070 |
Why?
|
| Carbon Radioisotopes | 2 | 2017 | 71 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2794 | 0.070 |
Why?
|
| Obesity | 1 | 2016 | 2082 | 0.060 |
Why?
|
| United States | 2 | 2019 | 10415 | 0.060 |
Why?
|
| Psychometrics | 2 | 2023 | 666 | 0.060 |
Why?
|
| Facial Expression | 1 | 2024 | 28 | 0.060 |
Why?
|
| Electrocorticography | 1 | 2024 | 59 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8088 | 0.050 |
Why?
|
| Glutamine | 1 | 2024 | 194 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 655 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 416 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2022 | 142 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 3066 | 0.050 |
Why?
|
| Prognosis | 1 | 2009 | 4477 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2020 | 115 | 0.040 |
Why?
|
| Maternal Behavior | 2 | 2010 | 65 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 205 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1473 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 9677 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 101 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1004 | 0.040 |
Why?
|
| Child | 3 | 2024 | 24035 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2024 | 1112 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 62 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 64 | 0.040 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 14 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2017 | 88 | 0.040 |
Why?
|
| Thalamus | 1 | 2017 | 83 | 0.040 |
Why?
|
| Motion | 1 | 2016 | 44 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 495 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1393 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 148 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2015 | 111 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 96 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1594 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 214 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 2533 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 355 | 0.030 |
Why?
|
| Mental Processes | 1 | 2014 | 41 | 0.030 |
Why?
|
| Oximes | 1 | 2014 | 46 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 158 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 544 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3521 | 0.030 |
Why?
|
| Genomics | 1 | 2020 | 1473 | 0.030 |
Why?
|
| Pyridines | 1 | 2014 | 222 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2012 | 14 | 0.030 |
Why?
|
| Dibenzothiazepines | 1 | 2012 | 12 | 0.030 |
Why?
|
| Aripiprazole | 1 | 2012 | 21 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2012 | 53 | 0.030 |
Why?
|
| Quinolones | 1 | 2012 | 54 | 0.030 |
Why?
|
| Auditory Cortex | 1 | 2012 | 30 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 88 | 0.020 |
Why?
|
| Risperidone | 1 | 2012 | 56 | 0.020 |
Why?
|
| Reaction Time | 1 | 2012 | 171 | 0.020 |
Why?
|
| Heart Rate | 1 | 2014 | 583 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 700 | 0.020 |
Why?
|
| Nesting Behavior | 1 | 2010 | 12 | 0.020 |
Why?
|
| Housing, Animal | 1 | 2010 | 18 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 920 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 227 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 62 | 0.020 |
Why?
|
| New York | 1 | 2010 | 66 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1209 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2769 | 0.020 |
Why?
|
| Life Change Events | 1 | 2010 | 59 | 0.020 |
Why?
|
| Object Attachment | 1 | 2010 | 52 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2010 | 166 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 707 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2010 | 491 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1311 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2007 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 755 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2011 | 476 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1103 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 3653 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1393 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1190 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 3619 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 4207 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 676 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4504 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 3222 | 0.010 |
Why?
|